Liquidia Corporation (LQDA)
Market Closed
16 Jun, 20:00
$
68. 01
-3.79
-5.2786%
After Hours
$
+1.99 +2.926% 70. 00
6.33B Market Cap
- P/E Ratio
- Div Yield
2.25M Volume
-1.15 Eps
$ 71.8
Previous Close 
Want to track LQDA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.36 per share a year ago.
Zacks | 1 year ago
Liquidia: Attractive Entry Point After Undeserved SCOTUS Appeal Reaction
The recent UTHR appeal to SCOUTS and the request for a LQDA answer caused an undeserved stock price drop. Interesting entry point as FDA potential approval remains imminent as more than 6 months passed since PDFUA date was delayed. The District Court ruling on patent 327 strengthens Liquidia's position against United's legal actions, as expected in our previous analysis.
Seekingalpha | 1 year ago
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Liquidia stock retook its 50-day line on a U.S. judge's ruling on a patent dispute with United Therapeutics.
Investors | 2 years ago
